#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Haemolytic uraemic syndrome Glioma Soft tissue sarcoma Pulmonary arterial hypertension Raynaud's phenomenon Nephropathy Synovitis Amyloidosis Ataxia telangiectasia Becker's muscular dystrophy Glycogen storage disease type II Cryoglobulinaemia Congenital myopathy Leukoencephalopathy Desmoid tumour More trials…

    Learn about Rare Diseases

    Von Willebrand’s disease – Basic Information Niemann-Pick disease – Treatment Pleural mesothelioma malignant – Treatment Alport’s syndrome – Treatment Pulmonary fibrosis – Basic Information Gaucher’s disease type III – Life with Disease Retinitis pigmentosa Marfan’s syndrome – Life with Disease Toxic epidermal necrolysis – Life with Disease Chronic granulomatous disease – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Thiamazole Leniolisib Phosphate Festuca Rubra Pollen Capsaicin NVG-2089 Kbp-336 Lauromacrogol 400 R3R01 Methohexital Sodium Nebivolol Hydrochloride Osilodrostat Alanine Sirexatamab Munc-T3 Ranolazine Napabucasin Retinol Palmitate Everolimus Caffeine Citrate Allogeneic Faecal Microbiota More therapies…

    Learn about Your Condition

    Malformation venous Mixed-type liposarcoma Chordoma Erectile dysfunction Cardiomyopathy HER2 negative breast cancer Vulvovaginal candidiasis Astrocytoma malignant Partial lipodystrophy Myotonic dystrophy Rett syndrome Hyperinsulinism Right ventricular dysfunction Coronary artery dissection Rectal cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Oesophageal carcinoma

  • A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal adenocarcinoma
    • Oesophageal carcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Fluorouracil
    France Germany Italy Poland Romania Spain

  • Study of drug combination therapy for patients with lymph node-positive esophageal and esophagogastric junction cancer using carboplatin, paclitaxel, fluorouracil, folinic acid, docetaxel and oxaliplatin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    • Oesophageal carcinoma
    Investigated Drugs:
    • Carboplatin
    • Docetaxel
    • Fluorouracil
    The Netherlands

  • Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastric cancer stage IV
    • Oesophageal carcinoma
    Investigated Drugs:
    • Calcium Levofolinate
    • Ivonescimab
    • Fluorouracil
    France

  • Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Metastatic gastric cancer
    • Gastric cancer
    • Oesophageal cancer metastatic
    Investigated Drugs:
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
    • Pembrolizumab
    Germany Greece Italy Poland Portugal Romania +1

  • Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

    Recruiting

    2 1 1
    Investigated Diseases:
    • Gastrointestinal carcinoma
    • Malignant neoplasm of ampulla of Vater
    • Salivary gland cancer
    Investigated Drugs:
    • 3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE
    • Bay 2927088
    • SEVABERTINIB
    Denmark France Italy Spain

  • Study of JK06 for Patients with Advanced or Metastatic Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Adenosquamous cell lung cancer
    • Bladder cancer
    Investigated Drugs:
    • Jk06
    Belgium Spain
1 2 3 … 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!